Saroglitazar Reduces Predictor Lipid Biomarkers Of Cardiovascular Diseases

Background and Aims: Dyslipidaemia is a known risk factor for cardiovascular diseases (CVDs). With the rising prevalence of dyslipidaemia, CVDs have emerged as major public health threats globally. Non high-density lipoprotein (non HDL)/HDL ratio and atherogenic index of plasma (AIP) are strong predictors of CVDs. Saroglitazar (Lipaglyn ®; Zydus Cadila, Ahmedabad, India) is a novel dual peroxisome proliferator activated receptor agonist and is approved in India for management of diabetic dyslipidaemia and hypertriglyceridemia in type 2 diabetes mellitus not controlled by statin alone.
Source: Atherosclerosis - Category: Cardiology Authors: Tags: E-poster session Source Type: research